Cargando…

Transcriptome analysis of intestine from alk-SMase knockout mice reveals the effect of alk-SMase

OBJECTIVE: Intestinal alkaline sphingomyelinase (alk-SMase) generates ceramide and inactivates platelet-activating factor associated with digestion and inhibition of cancer. There is few study to analyze the correlated function and characterize the genes related to alk-SMase comprehensively. We char...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Jiang, Wang, Lingqi, Guo, Zhongwu, Zhang, Tao, Zhang, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644495/ https://www.ncbi.nlm.nih.gov/pubmed/36348490 http://dx.doi.org/10.1186/s12935-022-02764-y

Ejemplares similares

Correction: Transcriptome analysis of intestine from alk-SMase knockout mice reveals the effect of alk-SMase
por: Zhu, Jiang, et al.
Publicado: (2022)

Transcriptome analysis alk-SMase knockout mice reveals the effect of alkaline sphingomyelinase on liver
por: Zhu, Jiang, et al.
Publicado: (2022)

Dendrimer-Conjugated nSMase2 Inhibitor Reduces Tau Propagation in Mice
por: Tallon, Carolyn, et al.
Publicado: (2022)

Microglial-Targeted nSMase2 Inhibitor Fails to Reduce Tau Propagation in PS19 Mice
por: Huang, Meixiang, et al.
Publicado: (2023)

Alpha‐mangostin improves endothelial dysfunction in db/db mice through inhibition of aSMase/ceramide pathway
por: Jiang, Meng, et al.
Publicado: (2021)

Inhibition of nSMase2 Reduces the Transfer of Oligomeric α-Synuclein Irrespective of Hypoxia
por: Sackmann, Valerie, et al.
Publicado: (2019)

The nSMase2/Smpd3 gene modulates the severity of muscular dystrophy and the emotional stress response in mdx mice
por: Matsuzaka, Yasunari, et al.
Publicado: (2020)

Stress-induced ceramide generation and apoptosis via the phosphorylation and activation of nSMase1 by JNK signaling
por: Yabu, T, et al.
Publicado: (2015)

Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in murine Alzheimer’s disease
por: Tallon, Carolyn, et al.
Publicado: (2023)

nSMase2 (Type 2-Neutral Sphingomyelinase) Deficiency or Inhibition by GW4869 Reduces Inflammation and Atherosclerosis in Apoe(−/−) Mice
por: Lallemand, Tom, et al.
Publicado: (2018)

Sphingomyelinase D Activity in Sicarius tropicus Venom: Toxic Potential and Clues to the Evolution of SMases D in the Sicariidae Family
por: Lopes, Priscila Hess, et al.
Publicado: (2021)

Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model
por: Tallon, Carolyn, et al.
Publicado: (2023)

The Expression of PHOSPHO1, nSMase2 and TNAP is Coordinately Regulated by Continuous PTH Exposure in Mineralising Osteoblast Cultures
por: Houston, D. A., et al.
Publicado: (2016)

Pharmacological inhibition of nSMase2 reduces brain exosome release and α-synuclein pathology in a Parkinson’s disease model
por: Zhu, Chunni, et al.
Publicado: (2021)

Early activation of nSMase2/ceramide pathway in astrocytes is involved in ischemia-associated neuronal damage via inflammation in rat hippocampi
por: Gu, LiZe, et al.
Publicado: (2013)

Neutral Sphingomyelinase 2 (nSMase2)-dependent Exosomal Transfer of Angiogenic MicroRNAs Regulate Cancer Cell Metastasis
por: Kosaka, Nobuyoshi, et al.
Publicado: (2013)

Correction to: Pharmacological inhibition of nSMase2 reduces brain exosome release and α-synuclein pathology in a Parkinson’s disease model
por: Zhu, Chunni, et al.
Publicado: (2021)

Tick-Borne Flavivirus Inhibits Sphingomyelinase (IsSMase), a Venomous Spider Ortholog to Increase Sphingomyelin Lipid Levels for Its Survival in Ixodes scapularis Ticks
por: Regmi, Pravesh, et al.
Publicado: (2020)

Therapeutic Application of Extracellular Vesicles-Capsulated Adeno-Associated Virus Vector via nSMase2/Smpd3, Satellite, and Immune Cells in Duchenne Muscular Dystrophy
por: Matsuzaka, Yasunari, et al.
Publicado: (2022)

Allosteric Inhibition of Neutral Sphingomyelinase 2 (nSMase2) by DPTIP: From Antiflaviviral Activity to Deciphering Its Binding Site through In Silico Studies and Experimental Validation
por: Álvarez-Fernández, Hadrián, et al.
Publicado: (2022)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

Inhibiting Extracellular Vesicle Release from Human Cardiosphere Derived Cells with Lentiviral Knockdown of nSMase2 Differentially Effects Proliferation and Apoptosis in Cardiomyocytes, Fibroblasts and Endothelial Cells In Vitro
por: Lang, Jennifer K., et al.
Publicado: (2016)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Identification of the Wallenda JNKKK as an Alk suppressor reveals increased competitiveness of Alk-expressing cells
por: Wolfstetter, Georg, et al.
Publicado: (2020)

Analysis of ALK gene in 133 patients with breast cancer revealed polysomy of chromosome 2 and no ALK amplification
por: Hanna, Matthew G., et al.
Publicado: (2015)

Hyperactivation of Alk induces neonatal lethality in knock-in Alk(F1178L) mice
por: Lopez-Delisle, Lucille, et al.
Publicado: (2014)

The role of Alk-1 and Alk-5 in the mechanosensing of chondrocytes
por: Sanz-Ramos, Patricia, et al.
Publicado: (2014)

Genomic and Transcriptomic Analysis of Neuroendocrine Transformation in ALK-Rearranged Lung Adenocarcinoma After Treatments With Sequential ALK Inhibitors: A Brief Report
por: Huang, Jie, et al.
Publicado: (2022)

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
por: Wang, Yuan, et al.
Publicado: (2022)

A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report
por: Guo, Jun, et al.
Publicado: (2020)

Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC
por: Xiao, Juanjuan, et al.
Publicado: (2022)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

22. COMPARATIVE EFFICACY OF ALK-INHIBITORS IN ALK INHIBITOR-NAIVE ALK+ LUNG CANCER BRAIN METASTASES: A NETWORK META-ANALYSIS
por: Haddad, Philip, et al.
Publicado: (2020)

A Bayesian network meta‐analysis of ALK inhibitor treatments in patients with ALK‐positive non‐small cell lung cancer
por: Zheng, Bei, et al.
Publicado: (2023)

Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2019)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_88bprkbbq9ec0te12h828qsb1g